New strategies for the treatment of hyperparathyroidism incorporating calcimimetics
- 17 March 2008
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Pharmacotherapy
- Vol. 9 (5), 795-811
- https://doi.org/10.1517/14656566.9.5.795
Abstract
Hyperparathyroidism (HPT), characterised by increased parathyroid hormone (PTH) secretion and parathyroid hyperplasia, can be caused by physiologic defects in the parathyroid gland (primary HPT [PHPT]) or as a consequence of declining renal function (secondary HPT [SHPT]). To review the safety and efficacy of cinacalcet in the treatment of SHPT and PHPT. Studies indexed in NLM/PubMed investigating the safety, efficacy, and pharmacokinetics of cinacalcet for PHPT and SHPT and supporting preclinical evidence. Recent evidence has demonstrated the efficacy of the calcimimetic cinacalcet in the treatment of PHPT and SHPT. Compared with traditional therapies such as vitamin D sterols and phosphate binders, cinacalcet treatment can allow an increased proportion of patients with SHPT to improve Kidney Disease Outcomes Quality Initiative (KDOQI) Bone Metabolism and Disease laboratory parameter target attainment. Recent evidence suggests that improvements in these biochemical parameters with cinacalcet can translate into improved morbidity and mortality. Cinacalcet lowers PTH and calcium in patients following renal transplantation, and also normalises serum calcium in patients with PHPT. Ongoing studies are focusing and future studies are likely to focus on the effect of cinacalcet on clinical outcomes and on novel strategies for the integration of cinacalcet with traditional therapies to improve serum PTH and mineral metabolism control.Keywords
This publication has 101 references indexed in Scilit:
- Cost utility analysis of cinacalcet in addition to standard of care in the UKNephrology Dialysis Transplantation, 2007
- Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patientsKidney International, 2007
- Novel Dosage Forms and Regimens for Sevelamer-Based Phosphate BindersJournal of Renal Nutrition, 2006
- Predictors and consequences of altered mineral metabolism: The Dialysis Outcomes and Practice Patterns StudyKidney International, 2005
- Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidismKidney International, 2005
- Overexpression of mutated Cu,Zn-SOD in neuroblastoma cells results in cytoskeletal changeAmerican Journal of Physiology-Cell Physiology, 2005
- Natural history of parathyroid function and calcium metabolism after kidney transplantation: a single-centre studyNephrology Dialysis Transplantation, 2004
- Phosphate binders in uraemia: pharmacodynamics, pharmacoeconomics, pharmacoethicsNephrology Dialysis Transplantation, 2002
- A deficit of calcitriol synthesis may not be the initial factor in the pathogenesis of secondary hyperparathyroidismNephrology Dialysis Transplantation, 1996
- Reduced Binding of [3H]l,25-Dihydroxyvitamin D3in the Parathyroid Glands of Patients with Renal FailureNew England Journal of Medicine, 1987